Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114652 | 0.94 | METAP2 (0.40) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL16115972 | 0.90 | L3MBTL1 (0.40) | METAP2ALDH1A1L3MBTL1 | |
| SCHEMBL4713295 | 0.84 | METAP2 (0.41) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL4425794 | 0.83 | METAP2 (0.43) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL892775 | 0.83 | METAP2 (0.43) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL4452637 | 0.83 | CTSK (0.43) | METAP2CTSKNPSR1TSHR | |
| SCHEMBL11021965 | 0.83 | METAP2 (0.43) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL1711503 | 0.83 | CTSK (0.43) | METAP2CTSKNPSR1TSHR | |
| SCHEMBL1711505 | 0.83 | CTSK (0.43) | METAP2CTSKNPSR1TSHR | |
| SCHEMBL17151664 | 0.83 | METAP2 (0.44) | METAP2ALDH1A1CTSKNPSR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008077647-A2 | ALPHA- AMINO ALCOHOLS AS NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077647-A2 | ALPHA- AMINO ALCOHOLS AS NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC1, PGRMC2 | METAP2 3719/4885ALDH1A1 1387/4885CTSK 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.